Summit Therapeutics Q3 2024 10-Q Filed

TL;DR

Summit Therapeutics filed its Q3 2024 10-Q, showing stock and capital activity.

AI Summary

Summit Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company's fiscal year ends on December 31st. The filing includes financial data for the third quarter of 2024, with specific details on common stock and additional paid-in capital transactions during the period from July 1, 2024, to September 30, 2024.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for Summit Therapeutics Inc., crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Summit Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.

Key Numbers

• 2024-09-30 — End of Reporting Period (The 10-Q covers financial data up to this date.)
• 2024-10-30 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
• 2024-07-01 to 2024-09-30 — Q3 2024 Period (Specific financial activities related to common stock and paid-in capital occurred during this quarter.)

Key Players & Entities

• Summit Therapeutics Inc. (company) — Filer of the 10-Q
• 2024-09-30 (date) — End of the reporting period
• 2024-10-30 (date) — Filing date
• 0001599298 (company) — Central Index Key for Summit Therapeutics Inc.
• 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share SMMT The Nasdaq S

Filing Documents

• smmt-20240930.htm (10-Q) — 999KB
• sum-ex311_20240930xduggan.htm (EX-31.1) — 12KB
• sum-ex312_20240930xzanganeh.htm (EX-31.2) — 12KB
• sum-ex313_20240930x10qsoni.htm (EX-31.3) — 12KB
• sum-ex321_20240930x10q.htm (EX-32.1) — 11KB
• smmt-20240930_g1.jpg (GRAPHIC) — 19KB
• smmt-20240930_g2.jpg (GRAPHIC) — 39KB
• 0001599298-24-000158.txt ( ) — 5769KB
• smmt-20240930.xsd (EX-101.SCH) — 49KB
• smmt-20240930_cal.xml (EX-101.CAL) — 57KB
• smmt-20240930_def.xml (EX-101.DEF) — 205KB
• smmt-20240930_lab.xml (EX-101.LAB) — 472KB
• smmt-20240930_pre.xml (EX-101.PRE) — 339KB
• smmt-20240930_htm.xml (XML) — 679KB

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 4 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 5 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2024 and 2023 6 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 8 Notes to Unaudited Condensed Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 24

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 37

Controls and Procedures

Item 4. Controls and Procedures 37 PART II

Legal Proceedings

Item 1. Legal Proceedings 38

Risk Factors

Item 1A. Risk Factors 38

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 38

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 38

Other Information

Item 5 Other Information 38

Exhibits

Item 6. Exhibits 39

Signatures

Signatures 39 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding the future financial performance, business prospects and growth of Summit Therapeutics Inc., that involve substantial risks and uncertainties. All statements contained in this Quarterly Report on Form 10-Q, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: the ability to develop a successful product candidate under the License Agreement (as defined below); our ability to raise sufficient additional funds to make payments under the License Agreement, and fund ongoing operations and capital needs; the timing of and the ability to effectively execute clinical development of ivonescimab; the timing, costs, conduct and outcomes of clinical trials for any product candidates; our plans with respect to possible future collaborations and partnering arrangements; the potential benefits of possible future acquisitions or investments in other businesses, products or technologies; our plans to pursue research and development of other future product candidates; our estimates regarding the po

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Summit Therapeutics Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (Unaudited) September 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 93,775 $ 71,425 Restricted cash 323 — Short-term investments 393,122 114,817 Prepaid expenses and other current assets 2,410 2,622 Research and development tax credit receivable 660 848 Total current assets 490,290 189,712 Non-current assets: Property and equipment, net 265 204 Right-of-use assets 7,976 5,859 Goodwill 1,991 1,893 Research and development tax credit receivable 467 959 Other assets 1,863 4,322 Total assets $ 502,852 $ 202,949 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,252 $ 2,667 Accrued liabilities 18,477 8,783 Accrued compensation 7,961 5,429 Lease liabilities 3,792 2,809 Other current liabilities 1,027 717 Promissory note payable to a related party 24,500 — Total current liabilities 59,009 20,405 Non-current liabilities: Lease liabilities, net of current portion 4,207 3,290 Other non-current liabilities 1,716 1,562 Promissory note payable to a related party — 100,000 Total liabilities 64,932 125,257 Commitments and contingencies (Note 18) Stockholders' equity: Preferred stock, $ 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at September 30, 2024 and December 31, 2023, respectively — — Common stock, $ 0.01 par value: 1,000,000,000 shares authorized; 737,094,965 and 701,660,053 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 7,371 7,017 Additional paid-in capital 1,586,227 1,066,381 Accumulated other comprehensive loss ( 2,308 ) ( 2,448 ) Accumulated deficit ( 1,153,370 ) ( 993,258 ) Total stockholders' equity 437,920 77,692 Total liabilities and stockholders' equity $ 502,852 $ 202,949 The accompanying notes are an integral part of the unaudited condense

View Full Filing

View this 10-Q filing on SEC EDGAR